Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination.
adjuvanted recombinant zoster vaccine
herpes zoster
persistence of immune response
safety
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
15 12 2021
15 12 2021
Historique:
received:
26
03
2020
accepted:
10
06
2020
pubmed:
6
6
2020
medline:
12
1
2022
entrez:
6
6
2020
Statut:
ppublish
Résumé
The adjuvanted recombinant zoster vaccine (RZV) is highly immunogenic and efficacious in adults ≥50 years of age. We evaluated (1) long-term immunogenicity of an initial 2-dose RZV schedule, by following up adults vaccinated at ≥60 years of age and by modeling, and (2) immunogenicity of 2 additional doses administered 10 years after initial vaccination. Persistence of humoral and cell-mediated immune (CMI) responses to 2 initial RZV doses was assessed through 10 years after initial vaccination, and modeled through 20 years using a Piecewise, Power law and Fraser model. The immunogenicity and safety of 2 additional RZV doses were also evaluated. Seventy adults were enrolled. Ten years after initial vaccination, humoral and CMI responses were approximately 6-fold and 3.5-fold, respectively, above those before the initial vaccination levels. Predicted immune persistence through 20 years after initial vaccination was similar across the 3 models. Sixty-two participants (mean age [standard deviation], 82.6 [4.4] years) received ≥1 additional RZV dose. Strong anamnestic humoral and CMI responses were elicited by 1 additional dose, without further increases after a second additional dose. Immune responses to an initial 2-dose RZV course persisted for many years in older adults. Strong anamnestic immune responses can be induced by additional dosing 10 years after the initial 2-dose course. NCT02735915.
Sections du résumé
BACKGROUND
The adjuvanted recombinant zoster vaccine (RZV) is highly immunogenic and efficacious in adults ≥50 years of age. We evaluated (1) long-term immunogenicity of an initial 2-dose RZV schedule, by following up adults vaccinated at ≥60 years of age and by modeling, and (2) immunogenicity of 2 additional doses administered 10 years after initial vaccination.
METHODS
Persistence of humoral and cell-mediated immune (CMI) responses to 2 initial RZV doses was assessed through 10 years after initial vaccination, and modeled through 20 years using a Piecewise, Power law and Fraser model. The immunogenicity and safety of 2 additional RZV doses were also evaluated.
RESULTS
Seventy adults were enrolled. Ten years after initial vaccination, humoral and CMI responses were approximately 6-fold and 3.5-fold, respectively, above those before the initial vaccination levels. Predicted immune persistence through 20 years after initial vaccination was similar across the 3 models. Sixty-two participants (mean age [standard deviation], 82.6 [4.4] years) received ≥1 additional RZV dose. Strong anamnestic humoral and CMI responses were elicited by 1 additional dose, without further increases after a second additional dose.
CONCLUSIONS
Immune responses to an initial 2-dose RZV course persisted for many years in older adults. Strong anamnestic immune responses can be induced by additional dosing 10 years after the initial 2-dose course.
CLINICAL TRIALS REGISTRATION
NCT02735915.
Identifiants
pubmed: 32502272
pii: 5851921
doi: 10.1093/infdis/jiaa300
pmc: PMC8672743
doi:
Substances chimiques
Adjuvants, Immunologic
0
Herpes Zoster Vaccine
0
Vaccines, Synthetic
0
Banques de données
ClinicalTrials.gov
['NCT02735915']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2025-2034Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
N Engl J Med. 2016 Sep 15;375(11):1019-32
pubmed: 27626517
N Engl J Med. 2015 May 28;372(22):2087-96
pubmed: 25916341
Neurology. 2013 Sep 3;81(10):928-30
pubmed: 23999562
Hum Vaccin Immunother. 2018 Jun 3;14(6):1370-1377
pubmed: 29461919
Gynecol Oncol. 2009 Dec;115(3 Suppl):S1-6
pubmed: 19217149
Mayo Clin Proc. 2017 Dec;92(12):1806-1821
pubmed: 29202939
Vaccine. 2014 Mar 26;32(15):1745-53
pubmed: 24508036
J Infect Dis. 2018 May 5;217(11):1750-1760
pubmed: 29529222
Vaccine. 2016 Feb 3;34(6):863-8
pubmed: 26432913
Vaccine. 2019 Apr 24;37(18):2482-2493
pubmed: 30935742
Curr Top Microbiol Immunol. 2010;342:341-57
pubmed: 20473790